Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds
CA 2218372 C · Owner: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. · Inventors: Savino, Rocco; Paonessa, Giacomo; Ciliberto, Gennaro
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to antagonists of human interleukin-6 that are totally incapable of binding the receptor chain responsible for transduction of the signal associated with this cytokine that is to say with gp 130. The , figure shows the lack of interaction between human interleukin-6 antagonists according to the invention and the protein gp 130.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 26, 1996 and granted July 31, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 26, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 26, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.